Valneva SE (VALN) is in Healthcare, Biotechnology, based in France, listed on NasdaqGS. Market cap 539.55M USD. 52-week range 4.75 to 12.18 USD. Data as of 2026-10-09.
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, ...